Multiple Myeloma/Chronic Lymphocytic Leukemia Coach RCT
NCT05928156 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 77
Last updated 2023-07-03
Summary
The purpose of this study is to test the effectiveness of evidence-informed mobile apps, Myeloma Coach and CLL Coach. These apps have been developed to help manage the physical and emotional symptoms experienced by multiple myeloma and chronic lymphocytic leukemia survivors. This study hopes to determine if a mobile app is a useful tool to help people manage commonly reported symptoms related to Multiple Myeloma (MM) and chronic lymphocytic leukemia (CLL).
Conditions
Interventions
- OTHER
-
Myeloma Coach or CLL Coach Mobile App
Symptom Tracking: Subjects will be asked to track their symptoms on a weekly basis, as well as given the opportunity to track these symptoms whenever they would like. Subjects will receive feedback tailored to their symptom severity with coaching on self management, including encouraging them to reach out to their health care team when symptoms are new, severe or increasing in severity. Subjects will also be able to look at graphs of symptom severity over time and share them with family and their health care team. Medication Adherence Reminders and Tracking, Activities - tools based on CBT (cognitive behavioral therapy) principles can be utilized at any time to manage emotional distress. Learn - information on cancer, its treatment, self managing physical and emotional symptoms, and supportive resources.
- OTHER
-
Springboard Beyond Cancer informational website
Springboard Beyond Cancer (https://survivorship.cancer.gov) is designed to make it easy for those in treatment and post-treatment to access essential information to help them manage ongoing cancer-related symptoms, deal with stress, improve healthy behaviors, communicate better with healthcare teams, and seek support from friends and family.
Sponsors & Collaborators
- lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-12-17
- Primary Completion
- 2021-09-19
- Completion
- 2021-09-19
Countries
- United States
Study Locations
More Related Trials
-
Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia
NCT00005829 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach
NCT00038415 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
NCT00492401 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
NCT00001586 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide
NCT01604031 ·Status: TERMINATED ·Phase: PHASE1
-
Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients
NCT00957385 ·Status: COMPLETED ·Phase: PHASE2
-
Natural History Study of Patients With Chronic Myelogenous Leukemia
NCT00429910 ·Status: COMPLETED
-
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
NCT07061951 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia
NCT01438138 ·Status: COMPLETED
-
Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia
NCT01057290 ·Status: COMPLETED
-
Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia
NCT00012259 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
NCT00352365 ·Status: COMPLETED ·Phase: PHASE2
-
2157GCCC:Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Dx AML
NCT04953780 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT01351896 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia
NCT01649791 ·Status: TERMINATED ·Phase: NA
-
Biomarker Study of Chemotherapy Resistance and Outcomes in Samples From Older Patients With Acute Myeloid Leukemia
NCT01421875 ·Status: COMPLETED
-
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
NCT05672355 ·Status: SUSPENDED ·Phase: PHASE2
-
Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia
NCT01271283 ·Status: WITHDRAWN ·Phase: PHASE2
-
Biomarkers in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia
NCT01298414 ·Status: COMPLETED
-
Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia
NCT01229956 ·Status: COMPLETED
-
Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS
NCT00744536 ·Status: COMPLETED ·Phase: PHASE2
-
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial
NCT02275533 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:
NCT05371808 ·Status: RECRUITING
-
Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction
NCT01578954 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
NCT05137860 ·Status: UNKNOWN ·Phase: PHASE4